|Bid||4.89 x 1100|
|Ask||4.92 x 1400|
|Day's Range||4.15 - 5.15|
|52 Week Range||3.40 - 9.59|
|Beta (5Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Moderna Inc has entered a licensing deal with Generation Bio Co to develop treatments targeting the immune system and liver, the latest such transaction by the vaccine maker as it expands beyond its COVID shots. Generation Bio's shares rose about 13.14% to $4.40 in premarket trading on Thursday. Moderna will pay $40 million in cash upfront, and make a $36 million equity investment in Cambridge, Massachusetts-based Generation Bio.
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.